22/01/2025 – AB Science announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors, that will take place on February 4, 2025, in Paris
17/12/2024 – AB Science provides a summary of the webcast held on December 16, 2024
16/12/2024 – Presentation of the AB Science webcast held on December 16, 2024
11/12/2024 – AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib
17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis
10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities
09/10/2024 – AB Science announces today that it has completed the settlement and delivery of the capital increase announced on September 30, 2024
30/09/2024 – The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024
30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros